We are a research and development-oriented drug discovery company, with a contractual structure whereby we receive revenues from payments on contracts to license development compounds, milestone revenues based on R&D progress, and royalties from sales of pharmaceutical products on the market.

RaQualia's management strategy is as follows:

1. 1. Expand our R&D Portfolio: Rather than focusing our management resources on a limited number of projects, we seek to have multiple projects and broaden our R&D portfolio.
2. 2. Promote Licensing: We make each aspect of our R&D portfolio available for licensing at every stage of development.
3. 3. Support Clinical Development: We seek to pave the way for the creation of running royalty revenues once drugs are launched on the market through post-licensing support of clinical development that prepares compounds for the market.

We believe these are essential elements for enhancing corporate value, and it will continue to be our policy to concentrate management resources in these areas.

This strategy will in turn enable us to efficiently mitigate risk, maximize revenue potential, and provide a stable pathway to long-term revenues.